Boland Lab Team
We are a team of translational scientists learning about cancer by studying patient-derived tumors and blood samples.
Genevieve Boland, MD, PhD
Genevieve M. Boland, MD, PhD, FACS is an Assistant Professor at Harvard Medical School and Director of the Melanoma Surgery Program at the Massachusetts General Hospital. Her primary clinical focus is on melanoma and cutaneous oncology. She undertook combined MD/PhD training, completing a PhD in Cell and Tissue Engineering at the National Institutes of Health focusing on signaling pathways in adult, human mesenchymal stem cells.
She graduated cum laude from Thomas Jefferson University as a member of the Alpha Omega Alpha medical honor society and completed her general surgical training at Massachusetts General Hospital. Following this, she completed a clinical fellowship in Complex General Surgical Oncology and a combined research fellowship at the University of Texas MD Anderson Cancer Center. She joined the MGH Division of Surgical Oncology and is focused on the clinical management of melanoma patients. She is board certified in General Surgery and Complex General Surgical Oncology, and she is a Fellow of the American College of Surgeons.
Tatyana Sharova, MD
Tatyana Sharova is a senior clinical research coordinator in the Boland Lab. She completed her Doctoral Degree in Oncology Hematology in Pediatrics in 1999. She has 15 years of intensive basic research at Boston University Department of Dermatology with a main focus on molecular and cell biology of skin and hair. Her technical skills including expertise in biochemical analysis of RNA and DNA, DNA cloning, protein handling, multi-color IHC and IF staining methods. For the last 10 years her work was primarily focused on skin derived cells, stem cells, and induced pluripotent stem cells. She is also a former lecturer for the unique International Graduate Program in Dermatology at BU. The combination of clinical and basic science knowledge was a good start to her career in clinical research, and she completed Clinical Research Coordinator Training and HIPAA Advanced Training. She also has expertise in FDA, GCP, HIPAA, and IRB regulations and guidelines.
William Michaud, PhD
William (Bill) Michaud is a research scientist in the Boland Lab. He obtained a PhD in Biology from the University of Maryland in 2001.
He worked in the Rocco Lab from 2001 – 2014 studying molecular changes in head and neck tumors, focusing on predictors of responsiveness to therapy. He joined the Boland Lab in 2014 and has optimized techniques for exosome extraction from cell culture and human sera, RNA preparation and analysis.
In additional to his technical expertise, Bill is a talented chef, brewmaster, biker and fisherman.
Gyulnara Kasumova, MD
Gyulnara Kasumova, MD is a general surgery resident at Dartmouth University. She has experience with clinical data analysis and outcomes work. Currently, she is focused on correlative analysis of molecular data in melanoma patients treated with immunotherapy. She oversees data collection/capture, clinical data analysis, and use for correlative studies. She is also focused on parallel analysis of multiple blood-based elements such as cell-free DNA, circulating exosomes, and serum plasma proteomics.
S. Alireza Rabi, MD, PhD
Ali is a general surgery resident at the Massachusetts General Hospital. He completed his combined MD/ PhD training at Johns Hopkins University. For his PhD thesis, he was mentored by Dr. Robert Siliciano, and he worked on delineating the mechanism by which protease inhibitors, a potent class of anti-retroviral drugs, achieve their anti-HIV-1 inhibitory potential.
For his research, he is interested in controlling the site of integration of lentiviruses. Lentiviruses integrate their genetic cargo into the genome of their host cells thus ensuring long-term and stable viral protein synthesis by the infected cells. In addition, they are capable of infecting non-dividing cells. These features make them very attractive for gene therapy applications. However, the genomic site of integration is largely unpredictable. This unpredictability can (and has) lead to oncogenesis which limits their use in in vivoapplications. His current project aims to control the site of lentiviral gene integration, thus rendering them safer for use in vivo.
Clinically, he is enrolled in the cardiac surgery track of the cardiothoracic integrated training program at MGH. He hopes to focus his fellowship training and subsequent career on heart and lung transplantation.
Xu Bai, MD
Xue (Catherine) Bai obtained an MD from Peking University in 2015 and has worked in Peking University Cancer Hospital as a medical oncologist since then. She joined the lab in 2017 and has been focusing on developing a predictive biomarker panel of MAPK pathway inhibitors in BRAF-mutant melanoma patients in the hope of identifying new intervention targets.
The Boland Lab works with a variety of collaborators to study patient-derived samples to ultimately improve the care of cancer patients.
A computer science and computational team focused on novel analytical approaches to scientific questions, now applying these to cancer data sets.
A translational research laboratory studying melanoma and the tumor microenvironment via mouse models of cancer.
A leading laboratory at Massachusetts General Hospital studying the basic biology and melanoma and other skin pathology.